Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

S0947000

Somatropin

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing


About This Item

CAS Number:
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

somatropin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Somatropin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Kuzma et al.
Bratislavske lekarske listy, 114(12), 689-695 (2013-12-18)
Growth hormone deficiency (GHD) is associated with reduced bone mineral content and increased risk of osteoporotic fractures. Reduced peak bone mass might explain the low bone mineral density (BMD) among patients with childhood onset GHD (CO-GHD) whilst the cause of
Bilal Battal et al.
The neuroradiology journal, 27(1), 55-62 (2014-02-28)
Brain herniations into dural venous sinuses (DVS) are rare findings recently described and their etiology and clinical significance are controversial. We describe five patients with brain herniations into the DVS or calvarium identified on MRI, and discuss their imaging findings
O V Bol'shova et al.
Likars'ka sprava, (5)(5), 70-75 (2014-03-13)
The objective was to study blood Zinc levels and hair Zinc content in three subsets of 40 naive patients (29 boys) with childhood onset GH deficiency (isolated total GHD, partial GHD, syndrome biological inactive GH). Our data showed that GHD
A Thankamony et al.
The Journal of clinical endocrinology and metabolism, 99(2), 639-647 (2014-01-16)
Data on the metabolic effects of GH derived from studies using GH suppression by pharmacological agents may not reflect selective actions. The purpose of this study was to evaluate the effects of GH antagonism on glucose and lipid metabolism using
E Elowe-Gruau et al.
Revue medicale suisse, 10(418), 424-424 (2014-03-20)
Children born premature and/or small for gestational age (SGA) are at risk of growth and metabolic abnormalities. Catch-up growth occurs usually before the age of 2. In the absence of sufficient catch up growth, growth hormone (GH) treatment should be

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service